CN114437065A - 杂环化合物，其制备方法和用途 - Google Patents

杂环化合物，其制备方法和用途 Download PDF

Info

Publication number
CN114437065A
CN114437065A CN202210122162.7A CN202210122162A CN114437065A CN 114437065 A CN114437065 A CN 114437065A CN 202210122162 A CN202210122162 A CN 202210122162A CN 114437065 A CN114437065 A CN 114437065A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210122162.7A
Other languages
English (en)
Chinese (zh)
Inventor
代星
王耀林
江岳恒
刘艳琴
史喆
王振武
陶良山
韩自省
牛浩涛
翁吉芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yifang Biotechnology Shanghai Co ltd
Original Assignee
Yifang Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yifang Biotechnology Shanghai Co ltd filed Critical Yifang Biotechnology Shanghai Co ltd
Publication of CN114437065A publication Critical patent/CN114437065A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202210122162.7A 2019-05-21 2020-05-20 杂环化合物，其制备方法和用途 Pending CN114437065A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN2019087772 2019-05-21
CNPCT/CN2019/087772 2019-05-21
CN2019095947 2019-07-15
CNPCT/CN2019/095947 2019-07-15
CN2019123223 2019-12-05
CNPCT/CN2019/123223 2019-12-05
PCT/CN2020/091274 WO2020233592A1 (en) 2019-05-21 2020-05-20 Heterocyclic compounds, preparation methods and uses thereof
CN202080004519.0A CN112585129B (zh) 2019-05-21 2020-05-20 杂环化合物，其制备方法和用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080004519.0A Division CN112585129B (zh) 2019-05-21 2020-05-20 杂环化合物，其制备方法和用途

Publications (1)

Publication Number Publication Date
CN114437065A true CN114437065A (zh) 2022-05-06

Family

ID=73459463

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210122162.7A Pending CN114437065A (zh) 2019-05-21 2020-05-20 杂环化合物，其制备方法和用途
CN202410157715.1A Pending CN118359609A (zh) 2019-05-21 2020-05-20 杂环化合物，其制备方法和用途
CN202080004519.0A Active CN112585129B (zh) 2019-05-21 2020-05-20 杂环化合物，其制备方法和用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410157715.1A Pending CN118359609A (zh) 2019-05-21 2020-05-20 杂环化合物，其制备方法和用途
CN202080004519.0A Active CN112585129B (zh) 2019-05-21 2020-05-20 杂环化合物，其制备方法和用途

Country Status (12)

Country Link
US (2) US11091481B2 (https=)
EP (1) EP3972967A4 (https=)
JP (2) JP7100210B2 (https=)
KR (1) KR102944305B1 (https=)
CN (3) CN114437065A (https=)
AU (1) AU2020279287B2 (https=)
BR (1) BR112021023136A2 (https=)
CA (1) CA3139348A1 (https=)
IL (1) IL288104B1 (https=)
MX (1) MX2021014096A (https=)
WO (1) WO2020233592A1 (https=)
ZA (1) ZA202110422B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116490188A (zh) * 2020-11-26 2023-07-25 上海翰森生物医药科技有限公司 含氮杂环类衍生物的盐、晶型及其制备方法和应用

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021120045A1 (en) * 2019-12-18 2021-06-24 InventisBio Co., Ltd. Heterocyclic compounds, preparation methods and uses thereof
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
CN113105448A (zh) * 2020-01-13 2021-07-13 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
WO2021143693A1 (zh) * 2020-01-13 2021-07-22 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN114671866A (zh) * 2020-12-25 2022-06-28 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN112159405B (zh) * 2020-02-04 2021-09-14 广州必贝特医药技术有限公司 吡啶并嘧啶酮类化合物及其应用
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
CN114901663B (zh) * 2020-03-02 2024-07-02 上海喆邺生物科技有限公司 一类芳香杂环类化合物及其在药物中的应用
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
CN114075195B (zh) * 2020-08-21 2026-04-28 广东东阳光药业股份有限公司 嘧啶酮衍生物及其在药物中的应用
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
JP2023544450A (ja) 2020-09-23 2023-10-23 エラスカ・インコーポレイテッド 三環式ピリドン及びピリミドン
WO2022111521A1 (zh) * 2020-11-24 2022-06-02 杭州多域生物技术有限公司 一种芳香化合物、其制备方法及应用
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
JP2023554476A (ja) * 2020-12-21 2023-12-27 アビスコ セラピューティクス カンパニー リミテッド 大環状ｋ－ｒａｓ ｇ１２ｃ阻害剤、その製造方法および使用
US20240189313A1 (en) * 2021-03-11 2024-06-13 InventisBio Co., Ltd. Solid dispersions
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
EP4473970A4 (en) 2022-03-31 2026-01-21 Eisai R&D Man Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS
CN117462553A (zh) * 2022-07-20 2024-01-30 益方生物科技(上海)股份有限公司 药物组合产品以及组合疗法
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2023439518A1 (en) 2023-04-06 2025-08-28 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202529768A (zh) 2023-09-29 2025-08-01 大陸商德昇濟醫藥（無錫）有限公司 癌症治療的療法
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025242126A1 (zh) * 2024-05-22 2025-11-27 上海正大天晴医药科技开发有限公司 一种药物组合及其应用
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119183A2 (en) * 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018217651A1 (en) * 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019051291A1 (en) * 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019213516A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
US11285156B2 (en) * 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
PE20260440A1 (es) 2018-11-09 2026-02-19 Hoffmann La Roche Compuestos de anillo fusionado
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CN110256421A (zh) 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
CN111377918B (zh) 2019-11-29 2021-03-02 苏州信诺维医药科技有限公司 一种kras抑制剂化合物
CN111205286B (zh) 2020-01-13 2022-12-13 中科苏州药物研究院 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119183A2 (en) * 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018217651A1 (en) * 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019051291A1 (en) * 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019213516A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116490188A (zh) * 2020-11-26 2023-07-25 上海翰森生物医药科技有限公司 含氮杂环类衍生物的盐、晶型及其制备方法和应用
CN116490188B (zh) * 2020-11-26 2026-01-30 上海翰森生物医药科技有限公司 含氮杂环类衍生物的盐、晶型及其制备方法和应用

Also Published As

Publication number Publication date
IL288104B1 (en) 2026-04-01
CN118359609A (zh) 2024-07-19
KR102944305B1 (ko) 2026-03-25
JP2022130631A (ja) 2022-09-06
AU2020279287A1 (en) 2021-12-16
US12110289B2 (en) 2024-10-08
JP7679338B2 (ja) 2025-05-19
JP2022525247A (ja) 2022-05-11
BR112021023136A2 (pt) 2022-01-04
MX2021014096A (es) 2022-02-11
CA3139348A1 (en) 2020-11-26
KR20220010542A (ko) 2022-01-25
EP3972967A4 (en) 2023-07-12
IL288104A (en) 2022-01-01
US20210355125A1 (en) 2021-11-18
EP3972967A1 (en) 2022-03-30
WO2020233592A1 (en) 2020-11-26
AU2020279287B2 (en) 2025-11-27
US11091481B2 (en) 2021-08-17
CN112585129B (zh) 2022-03-01
US20210198255A1 (en) 2021-07-01
JP7100210B2 (ja) 2022-07-12
ZA202110422B (en) 2024-03-27
CN112585129A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
CN112585129B (zh) 杂环化合物，其制备方法和用途
EP3399968B1 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
KR102614872B1 (ko) Hpk1 억제제 및 이의 사용 방법
EP3299367B1 (en) Biaryl amide compounds as kinase inhibitors
CN112739690A (zh) 用作smarca2拮抗剂的吡啶-2-酮化合物
EP3648753A1 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CN113316576A (zh) 用于治疗癌症的作为HPK1抑制剂的2,3-二氢-1H-吡咯并[3,4-c]吡啶-1-酮衍生物
CN109952300A (zh) 作为吲哚胺2,3-二加氧酶和/或色氨酸2,3-二加氧酶选择性抑制剂的新颖的5或8-取代的咪唑并[1,5-a]吡啶
CN111683662B (zh) 取代嘧啶类化合物及其药物组合物和治疗方法
WO2018030550A1 (en) Heterocyclic compounds with an ror(gamma)t modulating activity
KR20140123104A (ko) 유비퀴틴 활성화 효소의 피라졸로피리미디닐 억제제
KR20210125471A (ko) Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
CN119384420A (zh) 新型par-2抑制剂
CN115210236A (zh) 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
TWI894448B (zh) Ctla-4小分子降解劑及其應用
HK40041256B (en) Heterocyclic compounds, preparation methods and uses thereof
HK40041256A (en) Heterocyclic compounds, preparation methods and uses thereof
RU2828748C2 (ru) Гетероциклические соединения, способы их получения и применения
JP2024516194A (ja) Ｐｄ１／ｐｄ－ｌ１阻害剤としての化合物及びその方法
KR20250166190A (ko) Gpr35 조절제로서 이용하기 위한 이환식 헤테로아릴 화합물
HK40057478B (zh) Hpk1抑制剂及其使用方法
HK40053093A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
HK40004229A (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
HK40004229B (zh) Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20220506

Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Assignor: Yifang Biotechnology (Shanghai) Co.,Ltd.

Contract record no.: X2023990000968

Denomination of invention: Heterocyclic compounds, their preparation methods and uses

License type: Exclusive License

Record date: 20231207

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220506